Is the very low carbohydrate diet safe for individuals with chronic kidney disease?

Le résumé fourni par la source

Background: The very low carbohydrate diet (VLCHD) is gaining popularity as a therapy for metabolic syndrome. However, its effect on renal function in patients with comorbid moderate to severe chronic kidney disease (CKD) is currently unclear. Aim: This study analyses markers of kidney function in patients with metabolic syndrome and stages 3 and 4 CKD who undertook a VLCHD for at least 3 months. Setting: The study was conducted in a Mid North Coast general practice located in Port Macquarie, NSW, Australia, 2020–2022. Methods: Clinical data were analysed retrospectively from 18 participants with metabolic syndrome and CKD stages 3 and 4, who were prescribed a VLCHD (< 30 g carbohydrates/day). A linear mixed model was used to analyse markers of metabolic health (glycated haemoglobin (HbA1C), body mass index (BMI), blood pressure (BP), lipid profile (triglycerides and low-density lipoprotein cholesterol) and kidney function (estimated glomerular filtration rate (eGFR), serum creatinine, bicarbonate and urea)). Results: Strong evidence was found for reduced BMI (p < 0.001) and HbA1c (p < 0.001), despite reduced diabetic medications in 13/14 participants. Antihypertensive medications were reduced in 6/14 participants with no change in systolic BP. No changes were detected in eGFR or bicarbonate, while creatinine (p ≤ 0.001) and urea (p = 0.002) were reduced. No participants deteriorated to a more advanced stage of CKD; rather an absolute eGFR increase was found in 15/18 participants. Conclusion: For the first time, the VLCHD was demonstrated to reduce BMI, HbA1c, BP and medication burden in patients with CKD stages 3–4 without evidence of kidney damage. Contribution: The VLCHD could be a safe and effective therapy to improve metabolic health and consequently reduce cardiovascular disease risk in patients with metabolic syndrome and CKD.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.